Adaptive radiotherapy (up to 74 Gy) or standard radiotherapy (66 Gy) for patients with stage III non-small-cell lung cancer, according to [18F]FDG-PET tumour residual uptake at 42 Gy (RTEP7-IFCT-1402): a multicentre, randomised, controlled phase 2 trial. - Vera P; Thureau S; Le Tinier F; Chaumet-Riffaud P; Hapdey S; Kolesnikov-Gauthier H; Martin E; Berriolo-Riedinger A; Pourel N; Broglia JM; Boissellier P; Guillemard S; et al. (The Lancet. Oncology, 2024)